A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response

Plain-language summary

This observational study evaluated how c-MET levels and EGFR gene mutation relate to response to erlotinib treatment in patients with non-small cell lung cancer (NSCLC). It enrolled patients with advanced or metastatic NSCLC who had not responded to first-line chemotherapy. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Chonnam National University Hospital

Start date

9/1/2011

Estimated completion

11/1/2017

Countries

South Korea

Related genes

Locations

• Hwasun, South Korea

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Informed consent
* 19\~80 year old male or female
* Histologically proven advanced or metastatic NSCLC
* Failed to 1st line chemotherapy
* Tumor tissue for genetic analysis
* Evaluable target lesion by RECIST v1.1
* ECOG performance from 0 to 3
* Expected survival more than 12 weeks

Exclusion Criteria:

* Previous treatment of EGFR-tyrosine kinase inhibitors
* Severe hypersensitivity to erlotinib
* Residual toxicities (above grade 2) after previous chemotherapy
* Total bilirubin more than 1.5x of upper normal limit Liver function tests more than 2.5x of upper normal limits